Patients with newly diagnosed T2D, patients treated with non-hypoglycemic medications, patients who are at low risk for hypoglycemia, and patients who are motivated to scan their device several times per day
CGM devices without alarms/alerts
Patients preferring treatment with continuous subcutaneous insulin infusion (CSII)
Integrated CGM devices (iCGM) with the new insulin pumps/CGM-integrated automated insulin delivery (AID) insulin pump systems
Patients preferring treatment with multiple daily insulin injections (MDI)
New insulin ‘smart’ pens which accurately track dosages and injection times, and can be paired with one or more of the available CGM devices
Related articles
Patient awareness and attainment of goals in Type 2 Diabetes Mellitus: A real-world survey
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.
.png/jcr:content/science%20hero%20(1).png)
.jpg/jcr:content/diabetes%20thumb%20new%20(1).jpg)